PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions: Drug: Sigvotatug Vedotin
Drug: Pembrolizumab

First Posted Date: 2025-01-03

Last Posted Date: 2025-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 714

Registration Number: NCT06758401

Locations: 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸
BRCR Global, Plantation, Florida, United States
🇺🇸
Hope and Healing Cancer Services, New Lenox, Illinois, United States

and more 3 locations

Secondary Databased Post-marketing Surveillance Study of BNT162b2

Active, not recruiting

Conditions: COVID-19
SARS-CoV-2

Interventions: Biological: Tozinameran (BNT162b2)
Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

First Posted Date: 2024-12-19

Last Posted Date: 2025-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06743334

Locations: 🇰🇷
Pfizer, Soeul, Korea, Republic of

A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2024-12-16

Last Posted Date: 2025-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT06735742

A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Not yet recruiting

Conditions: Prostate Cancer

First Posted Date: 2024-12-13

Last Posted Date: 2025-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 104

Registration Number: NCT06733337

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: PF-07976016
Drug: Placebo

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-24

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT06717425

Locations: 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸
Westside Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
New Horizon Research Center, Miami, Florida, United States

and more 17 locations

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: PF-07264660
Other: Placebo

First Posted Date: 2024-12-02

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06712082

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07258669
Drug: Itraconazole

First Posted Date: 2024-11-27

Last Posted Date: 2025-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT06706869

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Tafamidis 61 mg free acid tablet (Test)
Drug: Tafamidis 61 mg free acid capsule (Reference)

First Posted Date: 2024-11-26

Last Posted Date: 2025-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT06705569

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1

Recruiting

Conditions: Carcinoma, Pancreatic Ductal
Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PF-07985045
Combination Product: Gemcitabine
Combination Product: Cetuximab
Combination Product: Fluorouracil
Combination Product: Pembrolizumab
Combination Product: PF-07284892
Combination Product: Nab-paclitaxel
Combination Product: Oxaliplatin
Combination Product: Sasanlimab
Combination Product: pemetrexed
Combination Product: Leucovorin
Combination Product: Cisplatin
Combination Product: Bevacizumab
Combination Product: Paclitaxel
Combination Product: Carboplatin

First Posted Date: 2024-11-26

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 190

Registration Number: NCT06704724

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 5 locations

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Phase 1

Not yet recruiting

Conditions: Severe Hemophilia A

Interventions: Drug: MARSTACIMAB

First Posted Date: 2024-11-25

Last Posted Date: 2025-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06703606

Home Terms & Conditions Privacy Policy